◎ Sugi Atlas

Atlas / Drug / Regadenoson Anhydrous

Regadenoson Anhydrous

drug
On this page

Also known as SID170465244Regadenoson

Summary

Regadenoson Anhydrous (CHEMBL317052) is an approved small molecule targeting ADORA1, ADORA2A, and ADORA2B; indicated across 4 conditions including coronary artery disorder and retinal artery occlusion.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • Targets: 4 (ADORA1, ADORA2A, ADORA2B…)
  • Indications: 4 conditions
  • Clinical trials: 54
  • Chemistry: 390.35 Da · C15H18N8O5

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL317052
NameRegadenoson Anhydrous
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID219024
Molecular formulaC15H18N8O5
Molecular weight390.35
InChIKeyLZPZPHGJDAGEJZ-AKAIJSEGSA-N

SMILES: CNC(=O)C1=CN(N=C1)C2=NC(=C3C(=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O)N

IUPAC name: 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]-N-methylpyrazole-4-carboxamide

Also known as: Regadenoson anhydrous, SID170465244, Regadenoson, REGADENOSON ANHYDROUS, regadenoson, REGADENOSON

Parent form; salt/anhydrous children: CHEMBL3989695

Patent coverage: 70 distinct patent families (186 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 164 (88%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
ADORA1A1 receptorAgonist50.3%P30542
ADORA2AA2A receptorAgonist6.540.4%P29274
ADORA2BA2B receptorAgonist50.5%P29275
ADORA3A3 receptorAgonist50%P0DMS8

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Adenosine receptor A1, Alpha-1A adrenergic receptor, Adenosine receptor A2a, Adenosine receptor A2b, Adenosine receptor A3, Adenosine receptor A2a.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 12 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
P305436.54Ki290nMCHEMBL_ACT_1236201
ADORA2A6.54Ki290nMCHEMBL_ACT_14644267
ADORA2A6.54Ki290nMCHEMBL_ACT_15210118
ADORA2A6.54Ki290nMCHEMBL_ACT_8031717
ADORA2A6.53Ki297nMCHEMBL_ACT_1466072
ADORA36.32AC50480.9nMCHEMBL_ACT_25199011
ADORA2A5.95Ki1120nMCHEMBL_ACT_1236202
ADORA35.43AC503700nMCHEMBL_ACT_25134557
ADORA15.42Ki3770nMCHEMBL_ACT_14644294
ADORA2B5EC5010000nMCHEMBL_ACT_14644283
ADORA35Ki10000nMCHEMBL_ACT_14644308

Target pathways

Aggregated over 4 target gene(s): ADORA1, ADORA2A, ADORA2B, ADORA3.

Top Reactome pathways

23 total, by targets touching each:

PathwayTargetsGenes
Signal Transduction4ADORA1, ADORA2A, ADORA2B, ADORA3
Signaling by GPCR4ADORA1, ADORA2A, ADORA2B, ADORA3
Class A/1 (Rhodopsin-like receptors)4ADORA1, ADORA2A, ADORA2B, ADORA3
GPCR downstream signalling4ADORA1, ADORA2A, ADORA2B, ADORA3
Adenosine P1 receptors4ADORA1, ADORA2A, ADORA2B, ADORA3
Nucleotide-like (purinergic) receptors4ADORA1, ADORA2A, ADORA2B, ADORA3
GPCR ligand binding4ADORA1, ADORA2A, ADORA2B, ADORA3
Metabolism of proteins2ADORA2A, ADORA2B
G alpha (s) signalling events2ADORA2A, ADORA2B
G alpha (i) signalling events2ADORA1, ADORA3
Surfactant metabolism2ADORA2A, ADORA2B
Disease1ADORA2B
Signaling by NTRKs1ADORA2A
Activation of TRKA receptors1ADORA2A
NGF-independant TRKA activation1ADORA2A
Signaling by NTRK1 (TRKA)1ADORA2A
Infectious disease1ADORA2B
Signaling by Receptor Tyrosine Kinases1ADORA2A
Leishmania infection1ADORA2B
ADORA2B mediated anti-inflammatory cytokines production1ADORA2B
Anti-inflammatory response favouring Leishmania parasite infection1ADORA2B
Leishmania parasite growth and survival1ADORA2B
Parasitic Infection Pathways1ADORA2B

Dominant GO biological processes

GO termTargets
signal transduction4
G protein-coupled receptor signaling pathway4
G protein-coupled adenosine receptor signaling pathway4
inflammatory response3
negative regulation of cell population proliferation3
vasodilation3
presynaptic modulation of chemical synaptic transmission3
phagocytosis2
cell-cell signaling2
response to purine-containing compound2
excitatory postsynaptic potential2
apoptotic signaling pathway2
negative regulation of inflammatory response2
adenylate cyclase-activating G protein-coupled receptor signaling pathway2
regulation of norepinephrine secretion2

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
coronary artery disorder3MONDO:0005010EFO:0001645
retinal artery occlusion2MONDO:0006948EFO:1001154
sickle cell disease2MONDO:0011382MONDO:0011382
myocardial ischemia1MONDO:0024644EFO:1001375

Clinical trials

Total trials: 54.

Phase distribution

PhaseTrials
Not specified17
PHASE413
PHASE27
PHASE16
EARLY_PHASE15
PHASE34
PHASE1/PHASE22

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03102125PHASE4RECRUITINGAllograft Dysfunction in Heart Transplant
NCT00862641PHASE4COMPLETEDA Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease
NCT00863707PHASE4COMPLETEDA Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
NCT00871260PHASE4COMPLETEDStress Testing and Cardiac Magnetic Resonance
NCT01109992PHASE4COMPLETEDIntegrated Dual Exercise and Lexiscan Positron Emission Tomography: IDEALPET
NCT01446094PHASE4UNKNOWNDiagnostic Study of Rapid Regadenoson Stress Cardiovascular Magnetic Resonance (CMR) to Detect Coronary Artery Disease
NCT01779869PHASE4COMPLETEDDevelopment of a PET-MR Myocardial Perfusion Examination Using Regadenoson
NCT01919450PHASE4COMPLETEDCharacterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation
NCT02115308PHASE4COMPLETEDCharacterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging
NCT02130453PHASE4COMPLETEDAccuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking
NCT02589977PHASE4COMPLETEDMyocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
NCT02597543PHASE4COMPLETEDStress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
NCT03249272PHASE4TERMINATEDMicrovascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
NCT00208299PHASE3COMPLETEDADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
NCT00208312PHASE3COMPLETEDADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
NCT00826280PHASE3COMPLETEDCaffeine’s Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
NCT01618669PHASE3COMPLETEDA Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)
NCT04604782PHASE1/PHASE2RECRUITINGA Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients
NCT00907764PHASE2TERMINATEDStress Echocardiography Study With Regadenoson
NCT01334918PHASE2COMPLETEDA Study of Regadenoson in Subjects Undergoing Stress Myocardial Perfusion Imaging (MPI) Using Multidetector Computed Tomography (MDCT) Compared to Single Photon Emission Computed Tomography (SPECT)
NCT01655043PHASE2COMPLETEDAbsolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI
NCT01788631PHASE2COMPLETEDA Phase II Trial of Regadenoson in Sickle Cell Anemia
NCT01840696PHASE2WITHDRAWNPhase Analysis and Obstructive CAD on Rubidium PET
NCT03090087PHASE2UNKNOWNThe Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo
NCT03236311PHASE2TERMINATEDA Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
NCT04606069PHASE1/PHASE2COMPLETEDTreat COVID-19 Patients With Regadenoson
NCT00837369PHASE1COMPLETEDRegadenoson R-T Perfusion Imaging Trial
NCT01161121PHASE1COMPLETEDComparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia
NCT01433705PHASE1COMPLETEDDistribution of Rubidium-82, Nitrogen-13 Ammonia, and Fluorine-18 Fluorodeoxyglucose in Normal Volunteers
NCT01918995PHASE1COMPLETEDRepeat Dose Tolerance Study of Regadenoson in Healthy Subjects
NCT03072589PHASE1UNKNOWNStudy to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation
NCT03971734PHASE1TERMINATEDDetermining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
NCT00763035EARLY_PHASE1TERMINATEDComparison of Dobutamine and Regadenoson Stress Cardiac Magnetic Resonance (MR)
NCT00881218EARLY_PHASE1COMPLETEDMyocardial Perfusion Magnetic Resonance Imaging Using Regadenoson
NCT02389738EARLY_PHASE1COMPLETEDBrain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
NCT04521569EARLY_PHASE1COMPLETEDRegadenoson Infusion of Marginalized Donor Lungs in an EVLP System
NCT04600115EARLY_PHASE1UNKNOWNNew MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT00857792Not specifiedCOMPLETEDMultivariable Assessment of Coronary Artery Disease Using Cardiac CT Imaging
NCT00859833Not specifiedCOMPLETEDEffects of Body Mass Index on the Hyperemic Response to Regadenoson
NCT00894179Not specifiedTERMINATEDSafety and Accuracy of Regadenoson-Atropine Stress Echocardiography in CAD

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 1 clinical and 7 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

476 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
ADENOSINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA2B, ADORA3
CAFFEINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA2B, ADORA3
ISTRADEFYLLINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA2B, ADORA3
THEOPHYLLINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA2B, ADORA3
BINODENOSONChEMBLPhase 3ADORA1, ADORA2A, ADORA2B, ADORA3
ROLOFYLLINEChEMBLPhase 3ADORA1, ADORA2A, ADORA2B, ADORA3
TONAPOFYLLINEChEMBLPhase 3ADORA1, ADORA2A, ADORA2B, ADORA3
TOZADENANTChEMBLPhase 3ADORA1, ADORA2A, ADORA2B, ADORA3
TRABODENOSONChEMBLPhase 3ADORA1, ADORA2A, ADORA2B, ADORA3
CIFORADENANTChEMBLPhase 2ADORA1, ADORA2A, ADORA2B, ADORA3
DERENOFYLLINEChEMBLPhase 2ADORA1, ADORA2A, ADORA2B, ADORA3
ENPROFYLLINEChEMBLPhase 2ADORA1, ADORA2A, ADORA2B, ADORA3
IMARADENANTChEMBLPhase 2ADORA1, ADORA2A, ADORA2B, ADORA3
TECADENOSONChEMBLPhase 2ADORA1, ADORA2A, ADORA2B, ADORA3
VIPADENANTChEMBLPhase 2ADORA1, ADORA2A, ADORA2B, ADORA3
FidaxomicinChEMBL + PubChemPhase 4 (approved)ADORA1, ADORA2A, ADORA3
LinagliptinChEMBL + PubChemPhase 4 (approved)ADORA1, ADORA2A, ADORA3
PyrazinamideChEMBL + PubChemPhase 4 (approved)ADORA1, ADORA2A, ADORA3
CLOFARABINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
CLOTRIMAZOLEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
ECONAZOLEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
EPALRESTATChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
FEDRATINIBChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
MEFLOQUINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
MICONAZOLEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
NEVIRAPINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
NIFEDIPINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
NIMESULIDEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
NISOLDIPINEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
NITAZOXANIDEChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
PENTOSTATINChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
PYRVINIUMChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
RIFAMPINChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
RIFAXIMINChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
SUNITINIBChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
TAMOXIFENChEMBLPhase 4 (approved)ADORA1, ADORA2A, ADORA3
APADENOSONChEMBLPhase 3ADORA1, ADORA2A, ADORA3
DIACEREINChEMBLPhase 3ADORA1, ADORA2A, ADORA3
NAMODENOSONChEMBLPhase 3ADORA1, ADORA2A, ADORA3
ETRUMADENANTChEMBLPhase 2ADORA1, ADORA2A, ADORA2B
METRIFUDILChEMBLPhase 2ADORA1, ADORA2A, ADORA3
SONEDENOSONChEMBLPhase 2ADORA1, ADORA2A, ADORA2B
TOFIMILASTChEMBLPhase 2ADORA1, ADORA2A, ADORA3
AfatinibPubChemApprovedADORA1, ADORA2A, ADORA3
ApixabanPubChemApprovedADORA1, ADORA2A, ADORA3
BinimetinibPubChemApprovedADORA1, ADORA2A, ADORA3
BosentanPubChemApprovedADORA1, ADORA2A, ADORA3
chenodiolPubChemApprovedADORA1, ADORA2A, ADORA3
DihydroergotaminePubChemApprovedADORA1, ADORA2A, ADORA3
FulvestrantPubChemApprovedADORA1, ADORA2A, ADORA3
ImipenemPubChemApprovedADORA1, ADORA2A, ADORA3
PropoxyphenePubChemApprovedADORA1, ADORA2A, ADORA3
ALPIDEMChEMBLPhase 4 (approved)ADORA1, ADORA3
AMPHETAMINEChEMBLPhase 4 (approved)ADORA1, ADORA2A
BALSALAZIDEChEMBLPhase 4 (approved)ADORA2A, ADORA3
BITHIONOLChEMBLPhase 4 (approved)ADORA2A, ADORA3
DAUNORUBICINChEMBLPhase 4 (approved)ADORA2A, ADORA3
ENASIDENIBChEMBLPhase 4 (approved)ADORA1, ADORA3
ERLOTINIBChEMBLPhase 4 (approved)ADORA2A, ADORA3

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot